News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tokai Pharmaceuticals Announces Presentation of Galeterone Mechanism of Action Data at American Association for Cancer Research Annual Meeting 2013



4/4/2013 6:34:30 AM

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that the company will present preclinical data highlighting the CYP17 lyase inhibition profile of galeterone in prostate cancer models at the American Association for Cancer Research (AACR) Annual Meeting 2013 in Washington, D.C.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES